CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

54.14 -3.20 (-5.58%)

Delayed Quote Updated: 12:18 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

37 38 Next >

1 Biotech Stock That Could Be the Next Amgen ↗

December 13, 2023

The emergence of genomic medicine as a viable modality could transform this midcap biotech into the next Amgen.

Via The Motley Fool

Better Growth Stock: Vertex Pharmaceuticals or Exact Sciences? ↗

December 13, 2023

Both of these biotech stocks have been market-beaters over the prior 10 years. One stock, however, is a better buy right now.

Via The Motley Fool

3 Gene-Editing Stocks With the Potential to Mint Millionaires ↗

December 13, 2023

Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR.

Via InvestorPlace

Cathie Wood's Ark Invest Sells Nearly $11.5M Worth Of Coinbase Shares As Bitcoin, Crypto Rally Loses Steam ↗

December 12, 2023

Via Benzinga

Here's What The FDA Approval Of Gene Editing For Sickle Cell Means For CRSP Stock And The Future Of Medicine ↗

December 12, 2023

Biotech stocks could be at a major turning point after FDA approval of the first gene editing drug using Crispr technology.

Via Investor's Business Daily

Is This News a Setback or a Step Forward for CRISPR Therapeutics? ↗

December 06, 2023

It's important to look at the news through a long-term lens.

Via The Motley Fool

Here's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today ↗

December 06, 2023

Via Benzinga

The Latest Analyst Ratings for CRISPR Therapeutics ↗

December 05, 2023

Via Benzinga

Could Intellia Therapeutics Become the Next CRISPR Therapeutics? ↗

December 12, 2023

Intellia is approaching the finish line.

Via The Motley Fool

Cathie Wood's Ark Dumps $12.8M Worth Of Grayscale Bitcoin Trust Amid Crypto Rally Losing Wind In Sails ↗

December 11, 2023

On Monday, Cathie Wood-led Ark Invest made a significant move by selling over $12.8 million worth of Grayscale Bitcoin Trust (OTC:GBTC) shares, amidst fluctuating cryptocurrency prices.

Via Benzinga

Why CRISPR Stock Keeps Falling ↗

December 11, 2023

CRISPR just scored its first FDA victory -- but profits remain years away.

Via The Motley Fool

3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023 ↗

December 11, 2023

Some of the most explosive opportunities can be found in biotech stocks. In fact, as we head into New Year 2024, here are three to consider.

Via InvestorPlace

HP To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Monday ↗

December 11, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Bull Of The Day: Crispr Therapeutics ↗

December 11, 2023

CRISPR Therapeutics (CRSP) just made history on Friday with the first FDA-approved gene-editing medicine based on the Nobel Prize-winning discovery that targets disease with the billion-year old...

Via Talk Markets

Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug? ↗

December 11, 2023

A simultaneous pair of approvals from the U.S. Food and Drug Administration gives investors new factors to consider.

Via The Motley Fool

The 3 Best Cathie Wood Stocks to Buy in December ↗

December 10, 2023

Cathie Wood stocks had a great November and are well-positioned to keep performing well, given the favorable macro backdrop.

Via InvestorPlace

Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy? ↗

December 10, 2023

The big biotech's shares have been on the rise this year.

Via The Motley Fool

FDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood Disorder ↗

December 08, 2023

The FDA has approved Casgevy and Lyfgenia, representing the first cell-based gene therapies for sickle cell disease in patients 12 y

Via Benzinga

Stock Market Rally Nears 2023 Highs; AMD, Google Jump On AI Push: Weekly Review ↗

December 08, 2023

Treasury yields and crude oil came off multimonth lows on Friday's jobs report.

Via Investor's Business Daily

Topics Artificial Intelligence

Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease

December 08, 2023

From Vertex Pharmaceuticals Incorporated

Via Business Wire

CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried? ↗

December 08, 2023

The timing of the cuts is setting off alarm bells, but the situation is under control.

Via The Motley Fool

Healthcare Gems: 3 Essential Long-Term Stock Picks ↗

December 07, 2023

Global healthcare spending reached a record $9 trillion in 2020. Catch the ongoing benefits with these three long-term healthcare stock picks.

Via InvestorPlace

This Newly Discovered Risk Could Be a Big Headache for Vertex Pharmaceuticals and CRISPR Therapeutics ↗

December 07, 2023

Shareholders will do well to prepare themselves for how regulators might react.

Via The Motley Fool

5 Unstoppable Trends to Invest $1,000 in for 2024 ↗

December 07, 2023

These next-big-thing trends represent some of the most exciting moneymaking opportunities for investors next year.

Via The Motley Fool

Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy ↗

December 07, 2023

These three gene therapy stocks should get huge boosts over the long term from the use of gene editing techniques to treat diseases.

Via InvestorPlace

CRISPR Therapeutics' Gene-Edited Oncology Pipeline To Focus On Expanded Use In Autoimmune Diseases ↗

December 05, 2023

Monday, CRISPR Therapeutics AG (NASDAQ: CRSP) provided an update on its immuno-oncology pipeline of CRISPR/Cas9 gene-edited allogeneic chimeric antigen receptor (CAR) T

Via Benzinga

Better Growth Stock: CRISPR Therapeutics vs. Invitae ↗

December 05, 2023

One of these stocks may be riskier than the other...

Via The Motley Fool

The Market's Up This Year. Do You Feel Like You Are Winning? ↗

December 04, 2023

We've also got a look at two stocks worth watching and the popular toys for this holiday season.

Via The Motley Fool

You Don't Have to Pick a Winner in Gene-Editing. Do This Instead. ↗

December 04, 2023

The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.

Via The Motley Fool

Where Will Vertex Pharmaceuticals Be in 10 Years? ↗

December 04, 2023

Vertex shares have soared 400% over the past decade.

Via The Motley Fool

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

37 38 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.